CAI Caris Life Sciences Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: CAI

Price (delayed)

$31.65

Market cap

$8.94B

P/E Ratio

18.62

Dividend/share

N/A

EPS

$1.7

Enterprise value

$8.65B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 93
Highlights
Caris Life Sciences's gross profit has surged by 141% YoY and by 11% QoQ
The net income has soared by 138% YoY
The quick ratio fell by 45% YoY and by 25% QoQ
CAI's debt is up by 5% year-on-year and by 3% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.carislifesciences.com
Peers: ILMN DGX BIO GH

Key stats

What are the main financial stats of CAI

CAI stock price

How has the Caris Life Sciences stock price performed over time
Intraday
0.57%
1 week
12.19%
1 month
20.48%
1 year
-1.4%
YTD
17.31%
QTD
77.61%

Financial performance

How have Caris Life Sciences's revenue and profit performed over time
Revenue
$989.61M
Gross profit
$689.36M
Operating income
$125.98M
Net income
$105.14M
Gross margin
69.7%
Net margin
10.6%
CAI's net margin has soared by 186% since the previous quarter and by 120% year-on-year
The operating income has soared by 166% YoY and by 43% QoQ
Caris Life Sciences's gross profit has surged by 141% YoY and by 11% QoQ
The net income has soared by 138% YoY

Price vs fundamentals

How does CAI's price correlate with its fundamentals

Growth

What is Caris Life Sciences's growth rate over time

Valuation

What is Caris Life Sciences stock price valuation
P/E
18.62
P/B
15.12
P/S
9.05
EV/EBIT
56.91
EV/EBITDA
48.55
EV/Sales
8.74
Caris Life Sciences's EPS has soared by 127% from the previous quarter and by 111% YoY
CAI's equity is up by 31% year-on-year
CAI's price to book (P/B) is 25% higher than its last 4 quarters average of 12.0
CAI's revenue has soared by 85% YoY and by 9% from the previous quarter
CAI's P/S is 23% higher than its last 4 quarters average of 7.3

Efficiency

How efficient is Caris Life Sciences business performance
CAI's ROIC has soared by 159% YoY and by 51% from the previous quarter
Caris Life Sciences's ROS has soared by 137% YoY and by 54% from the previous quarter
Caris Life Sciences's return on assets has surged by 124% QoQ and by 111% YoY
Caris Life Sciences's return on equity has surged by 124% QoQ and by 111% YoY

Dividends

What is CAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CAI.

Financial health

How did Caris Life Sciences financials performed over time
Caris Life Sciences's total assets is 93% more than its total liabilities
The quick ratio fell by 45% YoY and by 25% QoQ
Caris Life Sciences's current ratio has decreased by 40% YoY and by 22% QoQ
CAI's debt is 34% smaller than its equity
CAI's equity is up by 31% year-on-year
The debt to equity has declined by 20% year-on-year but it has increased by 3.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.